01—Abstract
Summary
Summary of the 10-K filed February 26, 2026. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported solid financial performance for the fiscal year ended December 31, 2025, with revenues reaching $44.56 billiona, a 4% increase compared to the previous year.
This growth was primarily driven by strong demand in the pharmaceutical and biotechnology sectors, although a slowdown in COVID-19 related product and service demand partially offset this. The company experienced robust productivity improvements across its segments, particularly in Laboratory Products and Biopharma Services and Life Sciences Solutions, leading to an increase in both GAAP operating income margin (17.4%b) and adjusted operating income margin (22.7%). Strategic acquisitions in 2025, including Olink Holding AB and a filtration and separation business, are expected to enhance Thermo Fisher's capabilities and market position, particularly in high-growth areas like proteomics and bioproduction.
While the company faces headwinds such as macroeconomic uncertainties impacting academic and government markets and increased costs due to inflation and tariffs, its diversified business model and focus on innovation position it well for continued growth. The company's financial position remains strong, supported by significant free cash flow generation and a substantial cash balance, enabling ongoing investments in R&D, strategic acquisitions, and shareholder returns.
02—Key points
Key Highlights
- Revenues increased by 4% to $44.56 billion in 2025, driven by pharma and biotech demand, despite a reduction in COVID-19 related product sales.
- GAAP operating income margin improved to 17.4% and adjusted operating income margin to 22.7%, reflecting strong productivity gains.
- The company completed strategic acquisitions in 2025, including Olink Holding AB (Life Sciences Solutions) and a filtration and separation business, to enhance its market offerings.
- Laboratory Products and Biopharma Services and Life Sciences Solutions segments showed strong organic revenue growth, contributing significantly to the company's performance.
- Despite some market softness in academic/government sectors and increased costs (tariffs, inflation), the company generated substantial free cash flow of $6.34 billion.
- Thermo Fisher ended the year with a strong liquidity position, holding $9.85 billion in cash and cash equivalents.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 26, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $44.56B$42.88B | +3.9% |
| R&D Expenses | $1.40B$1.39B | +0.5% |
| SG&A Expenses | $8.73B$8.60B | +1.6% |
| Operating Expenses | $36.81B$35.54B | +3.6% |
| Operating Income | $7.75B$7.34B | +5.6% |
| Net Income | $6.72B$6.34B | +6.0% |
| EPS (Basic) | $17.77$16.58 | +7.2% |
| EPS (Diluted) | $17.74$16.53 | +7.3% |
| Shares Outstanding (Basic) | 377.00M382.00M | −1.3% |
| Shares Outstanding (Diluted) | 378.00M383.00M | −1.3% |
05—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in 2025?
Revenue growth in 2025 was primarily driven by increased demand from pharmaceutical and biotechnology customers. Growth was also supported by acquisitions, including Olink Holding AB and a filtration and separation business, which expanded capabilities in high-growth markets.
How did the company's profitability change in 2025?
Profitability improved in 2025, with GAAP operating income margin increasing to 17.4% and adjusted operating income margin to 22.7%. This improvement was attributed to strong productivity enhancements through the company's PPI Business System, which helped offset unfavorable business mix and strategic investments.
What is the company's outlook for 2026 regarding its tax rate?
Thermo Fisher expects its GAAP effective tax rate for 2026 to be between 7% and 9%, and its adjusted tax rate to be approximately 11.5%.
How is the company managing its debt and liquidity?
The company's total debt increased to $39.38 billion in 2025. However, it maintains a strong liquidity position with $9.85 billion in cash and cash equivalents. It also has a $5.00 billion revolving credit facility available, demonstrating its capacity to meet financial obligations and pursue strategic initiatives.
What are the key risks identified by the company for its future operations?
Key risks include adverse impacts from general economic conditions, inflation, geopolitical instability, supply chain disruptions, cybersecurity threats, intense competition, and the ability to successfully integrate future acquisitions. Changes in government regulations and sustainability scrutiny also present potential challenges.
06—Continue